MEDICAL FACILITIES CORP (DR.CA) Fundamental Analysis & Valuation

TSX:DR • CA58457V5036

Current stock price

17.19 CAD
+0.02 (+0.12%)
Last:

This DR.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. DR.CA Profitability Analysis

1.1 Basic Checks

  • In the past year DR was profitable.
  • In the past year DR had a positive cash flow from operations.
  • Of the past 5 years DR 4 years were profitable.
  • Each year in the past 5 years DR had a positive operating cash flow.
DR.CA Yearly Net Income VS EBIT VS OCF VS FCFDR.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

1.2 Ratios

  • DR has a Return On Assets of 7.80%. This is amongst the best in the industry. DR outperforms 91.67% of its industry peers.
  • DR has a better Return On Equity (28.17%) than 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 19.99%, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • DR had an Average Return On Invested Capital over the past 3 years of 17.04%. This is significantly above the industry average of 6.93%.
  • The 3 year average ROIC (17.04%) for DR is below the current ROIC(19.99%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.8%
ROE 28.17%
ROIC 19.99%
ROA(3y)11.41%
ROA(5y)7.31%
ROE(3y)36.64%
ROE(5y)23.18%
ROIC(3y)17.04%
ROIC(5y)16.99%
DR.CA Yearly ROA, ROE, ROICDR.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

1.3 Margins

  • DR has a better Profit Margin (8.36%) than 100.00% of its industry peers.
  • DR's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 18.36%, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of DR has grown nicely.
  • The Gross Margin of DR (69.88%) is better than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of DR has remained more or less at the same level.
Industry RankSector Rank
OM 18.36%
PM (TTM) 8.36%
GM 69.88%
OM growth 3Y8.16%
OM growth 5Y9.83%
PM growth 3YN/A
PM growth 5Y28.17%
GM growth 3Y1.88%
GM growth 5Y0.92%
DR.CA Yearly Profit, Operating, Gross MarginsDR.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DR.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DR is creating value.
  • DR has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DR has been reduced compared to 5 years ago.
  • DR has a worse debt/assets ratio than last year.
DR.CA Yearly Shares OutstandingDR.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
DR.CA Yearly Total Debt VS Total AssetsDR.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • DR has an Altman-Z score of 1.49. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
  • DR has a Altman-Z score (1.49) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of DR is 2.47, which is a good value as it means it would take DR, 2.47 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 2.47, DR belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
  • A Debt/Equity ratio of 1.18 is on the high side and indicates that DR has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.18, DR perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
  • Even though the debt/equity ratio score it not favorable for DR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF 2.47
Altman-Z 1.49
ROIC/WACC2.49
WACC8.02%
DR.CA Yearly LT Debt VS Equity VS FCFDR.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.3 Liquidity

  • DR has a Current Ratio of 1.79. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
  • With an excellent Current ratio value of 1.79, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • DR has a Quick Ratio of 1.70. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.70, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.7
DR.CA Yearly Current Assets VS Current LiabilitesDR.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. DR.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.96% over the past year.
  • DR shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 41.82% yearly.
  • Looking at the last year, DR shows a very negative growth in Revenue. The Revenue has decreased by -23.34% in the last year.
  • Measured over the past years, DR shows a decrease in Revenue. The Revenue has been decreasing by -6.93% on average per year.
EPS 1Y (TTM)15.96%
EPS 3Y162.88%
EPS 5Y41.82%
EPS Q2Q%-16.95%
Revenue 1Y (TTM)-23.34%
Revenue growth 3Y-15.72%
Revenue growth 5Y-6.93%
Sales Q2Q%-17.54%

3.2 Future

  • DR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.70% yearly.
  • DR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.81% yearly.
EPS Next Y92.77%
EPS Next 2Y-20.43%
EPS Next 3Y3.7%
EPS Next 5YN/A
Revenue Next Year-21.82%
Revenue Next 2Y-10.47%
Revenue Next 3Y-8.81%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DR.CA Yearly Revenue VS EstimatesDR.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
DR.CA Yearly EPS VS EstimatesDR.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

9

4. DR.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.54, the valuation of DR can be described as very reasonable.
  • 91.67% of the companies in the same industry are more expensive than DR, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of DR to the average of the S&P500 Index (26.64), we can say DR is valued rather cheaply.
  • DR is valuated cheaply with a Price/Forward Earnings ratio of 5.99.
  • DR's Price/Forward Earnings ratio is rather cheap when compared to the industry. DR is cheaper than 91.67% of the companies in the same industry.
  • DR is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.54
Fwd PE 5.99
DR.CA Price Earnings VS Forward Price EarningsDR.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • DR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DR is cheaper than 100.00% of the companies in the same industry.
  • 83.33% of the companies in the same industry are more expensive than DR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 5.55
EV/EBITDA 4.42
DR.CA Per share dataDR.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • DR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of DR may justify a higher PE ratio.
PEG (NY)0.12
PEG (5Y)0.28
EPS Next 2Y-20.43%
EPS Next 3Y3.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. DR.CA Dividend Analysis

5.1 Amount

  • DR has a Yearly Dividend Yield of 2.14%.
  • DR's Dividend Yield is a higher than the industry average which is at 1.49.
  • DR's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.14%

5.2 History

  • The dividend of DR has a limited annual growth rate of 5.59%.
  • DR has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)5.59%
Div Incr Years0
Div Non Decr Years0
DR.CA Yearly Dividends per shareDR.CA Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • DR pays out 23.95% of its income as dividend. This is a sustainable payout ratio.
  • DR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP23.95%
EPS Next 2Y-20.43%
EPS Next 3Y3.7%
DR.CA Yearly Income VS Free CF VS DividendDR.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M
DR.CA Dividend Payout.DR.CA Dividend Payout, showing the Payout Ratio.DR.CA Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

DR.CA Fundamentals: All Metrics, Ratios and Statistics

MEDICAL FACILITIES CORP

TSX:DR (5/1/2026, 7:00:00 PM)

17.19

+0.02 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry Strength76.38
Industry Growth83.58
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners8.36%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap301.68M
Revenue(TTM)254.17M
Net Income(TTM)21.26M
Analysts42.22
Price Target16.58 (-3.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.14%
Yearly Dividend0.34
Dividend Growth(5Y)5.59%
DP23.95%
Div Incr Years0
Div Non Decr Years0
Ex-Date03-31
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.13%
Min EPS beat(2)6.33%
Max EPS beat(2)35.92%
EPS beat(4)2
Avg EPS beat(4)2.44%
Min EPS beat(4)-24.98%
Max EPS beat(4)35.92%
EPS beat(8)3
Avg EPS beat(8)-21.58%
EPS beat(12)5
Avg EPS beat(12)-26.43%
EPS beat(16)7
Avg EPS beat(16)-104.25%
Revenue beat(2)1
Avg Revenue beat(2)-9.99%
Min Revenue beat(2)-21.89%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-7.15%
Min Revenue beat(4)-21.89%
Max Revenue beat(4)1.91%
Revenue beat(8)2
Avg Revenue beat(8)-6.54%
Revenue beat(12)4
Avg Revenue beat(12)-4.25%
Revenue beat(16)4
Avg Revenue beat(16)-3.61%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)107.11%
EPS NY rev (3m)68.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.64%
Revenue NY rev (3m)-22.26%
Valuation
Industry RankSector Rank
PE 11.54
Fwd PE 5.99
P/S 0.87
P/FCF 5.55
P/OCF 4.94
P/B 2.93
P/tB N/A
EV/EBITDA 4.42
EPS(TTM)1.49
EY8.67%
EPS(NY)2.87
Fwd EY16.71%
FCF(TTM)3.1
FCFY18.01%
OCF(TTM)3.48
OCFY20.22%
SpS19.79
BVpS5.88
TBVpS-0.34
PEG (NY)0.12
PEG (5Y)0.28
Graham Number14.0359 (-18.35%)
Profitability
Industry RankSector Rank
ROA 7.8%
ROE 28.17%
ROCE 22.87%
ROIC 19.99%
ROICexc 25.4%
ROICexgc 50.53%
OM 18.36%
PM (TTM) 8.36%
GM 69.88%
FCFM 15.64%
ROA(3y)11.41%
ROA(5y)7.31%
ROE(3y)36.64%
ROE(5y)23.18%
ROIC(3y)17.04%
ROIC(5y)16.99%
ROICexc(3y)23.08%
ROICexc(5y)21.73%
ROICexgc(3y)54.96%
ROICexgc(5y)49%
ROCE(3y)19.49%
ROCE(5y)19.45%
ROICexgc growth 3Y4.72%
ROICexgc growth 5Y14.72%
ROICexc growth 3Y6.5%
ROICexc growth 5Y15.94%
OM growth 3Y8.16%
OM growth 5Y9.83%
PM growth 3YN/A
PM growth 5Y28.17%
GM growth 3Y1.88%
GM growth 5Y0.92%
F-Score5
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 1.18
Debt/FCF 2.47
Debt/EBITDA 1.43
Cap/Depr 31.15%
Cap/Sales 1.92%
Interest Coverage 9.31
Cash Conversion 71.63%
Profit Quality 187.05%
Current Ratio 1.79
Quick Ratio 1.7
Altman-Z 1.49
F-Score5
WACC8.02%
ROIC/WACC2.49
Cap/Depr(3y)47.39%
Cap/Depr(5y)41.2%
Cap/Sales(3y)3.17%
Cap/Sales(5y)2.64%
Profit Quality(3y)199%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.96%
EPS 3Y162.88%
EPS 5Y41.82%
EPS Q2Q%-16.95%
EPS Next Y92.77%
EPS Next 2Y-20.43%
EPS Next 3Y3.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.34%
Revenue growth 3Y-15.72%
Revenue growth 5Y-6.93%
Sales Q2Q%-17.54%
Revenue Next Year-21.82%
Revenue Next 2Y-10.47%
Revenue Next 3Y-8.81%
Revenue Next 5YN/A
EBIT growth 1Y-10.18%
EBIT growth 3Y-8.84%
EBIT growth 5Y2.22%
EBIT Next Year-6.97%
EBIT Next 3Y-3.63%
EBIT Next 5YN/A
FCF growth 1Y-47.83%
FCF growth 3Y-7.53%
FCF growth 5Y-12.96%
OCF growth 1Y-46.4%
OCF growth 3Y-7.83%
OCF growth 5Y-12.51%

MEDICAL FACILITIES CORP / DR.CA Fundamental Analysis FAQ

What is the fundamental rating for DR stock?

ChartMill assigns a fundamental rating of 6 / 10 to DR.CA.


What is the valuation status of MEDICAL FACILITIES CORP (DR.CA) stock?

ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.


What is the profitability of DR stock?

MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 9 / 10.


What is the valuation of MEDICAL FACILITIES CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 11.54 and the Price/Book (PB) ratio is 2.93.


How financially healthy is MEDICAL FACILITIES CORP?

The financial health rating of MEDICAL FACILITIES CORP (DR.CA) is 6 / 10.